A small human biopsy study found increased staining for a marker associated with apoptosis after combined HIFEM and RF treatment; the reported apoptotic index is not a percentage of body fat removed.
Place the biopsy result on its own timeline
This apoptosis study examined tissue after one treatment, with sampling at eight and twenty-four hours. A cellular marker is a different endpoint from measured fat-layer reduction or an individual visible result.
What happens to fat cells in the weeks after EMSCULPT NEO? · Muscle size, strength and everyday function: what do the measurements mean?
Study at a glance
Design: Small, randomised active-versus-sham human histology study.
Participants: Nine enrolled (six active, three sham); seven analysed (five active, two sham).
Research protocol: One abdominal HIFEM+RF treatment.
Follow-up: Baseline, eight and 24 hours; safety visit at seven days.
Evidence visual: An apoptosis marker is not a fat-loss percentage
The denominator is counted nuclei in evaluated tissue sections.
Eight hours
Active group staining index: 47.01 % apoptotic index.
Caspase-3-positive nuclei / evaluated adipocyte nuclei. Not 47.01% of body fat removed.
24 hours
Active-group staining index at 24 hours: 43.58% in the abstract; 43.72% in the full results. This discrepancy remains unresolved.
A second early tissue-sampling point, not a chart of visible results or permanence.
Comparison and sample
Nine enrolled; two biopsies were unsuitable. Seven participants were analysed: five active and two sham. Sham change was not significant.
Source for the visual: [S09]. No body-shape simulation and no exact-zero sham value. The index is a tissue marker, not an individual forecast.
Looking for a mechanism, not just a change in appearance
Imaging studies can show that a tissue measurement changed. A biopsy study asks a different question: what cellular changes were present in a small sample of that tissue?
Goldberg's 2024 study examined an early marker associated with apoptosis after combined HIFEM and synchronised RF treatment. Apoptosis is a regulated process of cell death. The investigators used staining for caspase-3, a protein involved in that process, to investigate changes in sampled abdominal fat. [S09]
This is mechanism evidence. It helps explain a biological observation, but it is not itself a measurement of how much fat a patient loses or how their abdomen will look.
For treatment background, read What is EMSCULPT NEO?. This article focuses on the specific research question.
How the early biopsy study was designed
Nine people were enrolled and assigned to active treatment or sham: six active and three sham. The protocol involved one abdominal treatment, with tissue sampling at baseline and at eight and 24 hours, followed by a safety visit at seven days. The comparison used low energy settings. [S09]
The full results report two exclusions for unsuitable biopsies, leaving five active and two sham participants in the analysis. [S09]
A small, controlled tissue study can be useful for mechanism. It does not have the scope of a large clinical trial designed to establish the chance of a visible patient benefit.
What is the apoptotic index?
The study's apoptotic index was the ratio of positively stained nuclei to the adipocyte nuclei counted in the evaluated tissue sections. Both sections report 47.01% at eight hours. At 24 hours, the abstract gives 43.58%, while the full results give 43.72%; neither is presented here as a settled value. The sham group did not show a significant change. [S09]
The denominator is crucial: counted nuclei in evaluated biopsy sections. It is not all fat cells in the abdomen, all fat in the body or the patient's total body weight.
A numerical visual can be helpful only if that definition stays attached. The visual labels the result as a staining index; it does not represent half of a person's body fat disappearing.
Why 47% staining does not mean 47% fat loss
An early biological marker and a later clinical outcome are different kinds of measurement. A positive stain is evidence about the sampled tissue at that timepoint. It does not directly measure the volume of fat ultimately removed, the number of cells remaining months later or the final change in contour.
The phrase “47% fat-cell death” would therefore omit important methodological context. “47% of body fat removed” would be a much larger and unsupported claim.
The most accurate explanation keeps the chain of evidence in order: this study investigated an early marker in tissue samples; other studies examined later anatomy; neither step creates a guaranteed personal result.
Why eight and 24 hours were measured
The early sampling schedule was designed to look for cellular activity soon after treatment. It should not be repurposed as an estimate of when a patient will see their final contouring result. [S09]
There is no valid countdown from a marker measured at eight hours to a particular appearance at eight hours. A biological mechanism can begin before a meaningful external change is visible, and the study does not quantify that relationship for an individual.
The same principle applies to the comparison between the two indices. A lower value at 24 hours than at eight hours does not mean the clinical result has “worn off”. These are observations at two sampling times, not a validated personal progress curve.
How this fits with MRI and ultrasound evidence
The biopsy findings and imaging studies are complementary because they ask different questions. The sham-controlled abdominal study assessed local fat and muscle thickness over months. The earlier histological study examined tissue changes one week and one month after a course. [S01, S10]
Reading the studies together can make the scientific explanation more coherent, but the percentages must not be added, averaged or turned into a single expected-result formula. A staining index, cell area and fat-layer thickness do not have a shared denominator.
Likewise, this human biopsy study should not be illustrated using animal results without clear labelling. Human and animal evidence belong in different categories, even when both contribute to understanding a mechanism.
Does a biological effect mean treatment is appropriate?
Not by itself. A device can produce a measurable biological effect and still be unsuitable for a particular person or unhelpful for their main concern. The decision must consider the treatment goal, likely benefit, alternatives, risks and relevant medical history.
For ¹EM, the value of mechanism education is clarity, not pressure. A patient should be able to understand why a procedure is being proposed without feeling that a laboratory marker obliges them to proceed.
Safety and source transparency
No treatment-related adverse events were reported in the abstract, but nine enrolled participants and short follow-up cannot exclude uncommon or longer-term harms. General magnetic-field and RF screening remains necessary. [S09, G01]
The full commercial-support and disclosure details were not verified in the accessible source. The paper is not labelled independent, and the staining results are not translated into unsupported claims about permanent fat removal.
The conclusion is specific: the study reported early changes in a marker associated with apoptosis in sampled human fat after the combined treatment. That is useful mechanism evidence, not a personal fat-loss percentage.
Frequently asked questions
What did the researchers find in the biopsies?
The eight-hour index was 47.01%. The 24-hour value differs between the abstract (43.58%) and results (43.72%). These are tissue-staining measurements. [S09]
Does 47.01% mean nearly half my abdominal fat will disappear?
No. The percentage describes a staining index in evaluated biopsy sections. It is not a measurement of the amount of abdominal fat removed or an individual contour result. [S09]
Was this a human or animal study?
A human study: nine enrolled; seven analysed, including five active and two sham participants. [S09]
Will the final visible result appear within 24 hours?
The early biopsy timepoints do not establish a visible-result deadline. They were chosen to examine cellular markers, not to determine when a patient would achieve a final contour. [S09]
Can the apoptosis percentage be added to the MRI fat-reduction percentage?
No. The studies measure different endpoints with different denominators. Adding them would create a number that no study measured.
Sources
[S09] Goldberg DJ. Induction of fat apoptosis by a combination of synchronized radiofrequency and HIFEM technology: Human histology study. Journal of Cosmetic Dermatology. 23(3):812–817. 2024. DOI: 10.1111/jocd.16197. https://onlinelibrary.wiley.com/doi/10.1111/jocd.16197
[S01] Samuels JB, Katz B, Weiss RA. Radiofrequency Heating and High-Intensity Focused Electromagnetic Treatment Delivered Simultaneously: The First Sham-Controlled Randomized Trial. Plastic and Reconstructive Surgery. 149(5):893e–900e. 2022. DOI: 10.1097/PRS.0000000000009030. https://pmc.ncbi.nlm.nih.gov/articles/PMC9028295/
[S10] Goldberg DJ. Deletion of adipocytes induced by a novel device simultaneously delivering synchronized radiofrequency and HIFEM: Human histological study. Journal of Cosmetic Dermatology. 20(4):1104–1109. 2021. DOI: 10.1111/jocd.13970. https://onlinelibrary.wiley.com/doi/10.1111/jocd.13970
[G01] US Food and Drug Administration. Non-Invasive Body Contouring Technologies. Patient information. 2026. https://www.fda.gov/medical-devices/aesthetic-cosmetic-devices/non-invasive-body-contouring-technologies
Practical information
Start with an individual assessment
General information cannot determine whether treatment is right for you. Request a private assessment with the ¹EM team.
General educational information, not individual medical advice. Published research findings are not ¹EM patient-outcome data. Suitability, experience and results vary.